well results were obviously worse for this 25 patients than the...

well results were obviously worse for this 25 patients than the first 125 on average (as it reduced the average).... but, take out patients 76-100 which had ~ 60% pain reduction and this is the same positive results as the first 75 patients reported on.....

sure, there will likely be a batch or two that end up being worse results than the average....as there will be a batch or two that are better than the average....

perhaps a few disappointed that this wasn't ~60% pain reduction when it appears the results were based on the similar 6 week patient timeframe.... this afterall, is what they indicated had led to the last 25 patients being at 60%....

but considering the two quotes below... there is nothing at all worng with 50%....

"The pain reducing effects of iPPS are considered significantly superior than the typical 15% pain reduction scores reported for opioid treatments for chronic pain in OA of the knee and hip." (all while a massive opioid addiction problem in the USA, and well and truly understood by the FDA)

“Clinically meaningful reduction of chronic pain has been defined to be between 25-30% pain reduction”



i wonder if there is a few holders that made the same mistake as me and looked at the forecast cash spend for the sept quarter and the june cash balance and thought a CR was imminent....

i hadn't done my research and it wasn't until i'd read @Dungiven 's post below that i realised they had cash receipts coming in to see them through the trials....so no need for a raise yet...

https://hotcopper.com.au/threads/tim-boreham-whats-next-for-par.4450643/?post_id=35789696

there was $1mil in options conversion money and a $2m R&D tax incentive due in Sept...